Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Apple Turns 50: From Garage Startup to AI Crossroads 
Britain Courts Anthropic Amid US Defense Department Dispute 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
EAST RUTHERFORD, N.J., Oct. 03, 2016 -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced the validation and ISO certification of a new pilot plant at its state-of-the-art manufacturing and R&D site in Paullo (MI), Italy.
The cGMP plant, which can produce batch sizes from 1kg to 15kg, was constructed in order to meet customer demand for small-scale API volumes, both for validation to support a DMF filing for Abbreviated New Drug Applications or generic registrations, and for API supply to niche markets, including ophthalmic drugs. The new facility will also provide custom manufacturing of NCEs and intermediates for early stage drug development and clinical trials.
“We currently have a product portfolio comprising over 70 generic APIs, which are manufactured under cGMP, for the global generic pharmaceutical industry,” commented Aldo Magnini, Managing Director, Cambrex Milan. “We have invested in the pilot plant to expand our small-scale volume offering for customers worldwide and to give us greater speed, flexibility and capacity in this market space.”
The new facility is equipped with a hydrogenator that can operate at 30 Bar and two separate lines of 150 liter glass lined and stainless steel reactors. ISO 8 classified, the plant is also equipped with a static dryer, milling and micronization capabilities.
Cambrex plans a further upgrade of the pilot plant in 2017 to support production of Class 3/4 high potency products.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Alex Maw Director, Marketing and Communications Phone: +44 7803 443 155 Email: [email protected]
